The results indicated an enhanced tumor elimination process, lower tumor burden, greater accumulation of infiltrating CD8 + T cells in the tumor, while paired with no adverse effects in mice given PAPP-A-2G6 TCR transgenic T cells. The gene discussed is CD8A; the disease is neoplasm.